Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Operations (2019 - 2025)

Goldenwell Biotech (GWLL) has disclosed Cash from Operations for 7 consecutive years, with 30885.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 84.22% year-over-year to 30885.0, compared with a TTM value of 29132.0 through Sep 2025, up 74.13%, and an annual FY2024 reading of 123077.0, down 8.77% over the prior year.
  • Cash from Operations was 30885.0 for Q3 2025 at Goldenwell Biotech, down from 59381.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 59381.0 in Q2 2025 and bottomed at 917090.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 89448.32, with a median of 29010.0 recorded in 2024.
  • The sharpest move saw Cash from Operations tumbled 105675.35% in 2021, then skyrocketed 224.36% in 2025.
  • Year by year, Cash from Operations stood at 19373.0 in 2021, then plummeted by 4633.86% to 917090.0 in 2022, then soared by 97.92% to 19076.0 in 2023, then plummeted by 32.89% to 25351.0 in 2024, then decreased by 21.83% to 30885.0 in 2025.
  • Business Quant data shows Cash from Operations for GWLL at 30885.0 in Q3 2025, 59381.0 in Q2 2025, and 32277.0 in Q1 2025.